Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Cytokine. 2016 Oct 26;90:66–72. doi: 10.1016/j.cyto.2016.10.013

Figure 2. Treatment modifies the systemic cytokine profile in TBL.

Figure 2

Figure 2

(A) The systemic concentrations of Type 1 (IFNγ, TNFα, IL-2) and Type 17 (IL-17A, IL-17F, IL-22) cytokines were measured in TBL (n=31) individuals before (pre-T) and 6 months after (post-T) anti-TB treatment. (B) The systemic concentrations of pro-inflammatory (IL-1α, IL-1β, IL-12 and IL-18) and regulatory (IL-10, TGFβ) cytokines were measured in TBL (n=31) individuals before (pre-T) and 6 months after (post-T) anti-TB treatment. The results are shown as line diagrams with each line representing a single individual. P values were calculated using the Wilcoxon signed rank test with Holm’s correction for multiple comparisons.